Dr Reddy's Laboratories and ClinTec International have entered into an agreement for the joint development of an anti-cancer compound, DRF 1042.According to a release issued by Dr Reddy's to the BSE today, the company retains the commercialisation rights for the US and rest of the world excluding ClinTec International territories that include the major European markets.
